Abstract
Background. COVID-19 is a viral disease that puts elderly patients with obesity, diabetes mellitus, chronic lung disease, cardiovascular disease, chronic kidney disease, chronic liver disease, and neoplastic conditions at risk of severe COVID-19 and related complications. Are with it. The importance of paying attention to hematological disorders in COVID-19 patients should be considered because the monitoring of hematological indicators may improve the prognosis of hospitalized patients with COVID-19. The present study was conducted with the aim of determining the prevalence of hematological disorders in hospitalized patients with COVID-19.
Methods. A cross-sectional study was conducted in patients admitted to Rasoul Akram Hospital in Tehran with the diagnosis of COVID-19. Inclusion criteria included patients with definite diagnosis of COVID-19 through PCR-RT test and age 18 years and older. Age, gender, laboratory values and clinical results, including the duration of hospitalization in the ICU, and the total time of hospitalization and finally death or discharge were registered. Platelet count less than 150,000/µL was considered thrombocytopenia and hemoglobin less than 13 g/dL in men and less than 12 g/dL in women was considered anemia.
Results. 1020 patients met the inclusion criteria and were included in the final analysis. Of these, 590 (57.8%) were men and 430 (42.2%) were women. The mean age of the patients was 60.18 ± 16.43 years (18-97 years). The mean time of hospitalization in the patients participating in the study was 7.74 ± 6.76 days (1-51 days). A total of 254 people (24.9%) were hospitalized and treated in the intensive care unit. About 30% (302 people out of 1020 people) of the patients participating in the study had thrombocytopenia of different severity and about 39% of the patients (395 people out of 1020 people) had anemia.
Conclusion. It can be concluded that thrombocytopenia as one of the accompanying variables in COVID-19 patients has little importance in the recovery process and disease outcomes. While anemia can be one of the most effective variables that even plays a role in the death of patients, so it needs timely intervention and should be considered during the patient's treatment period.
Practical Implications. Determining the prevalence of hematological disorders in hospitalized patients diagnosed with COVID-19.